Cytokinetics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 564

Market Cap: $6.5B

Website

Clinical Trials

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Phase 3

Recruiting

Conditions: Heart Failure
Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Omecamtiv Mecarbil (OM)
Drug: Placebo

First Posted Date: 2024-12-16

Last Posted Date: 2024-12-16

Lead Sponsor: Cytokinetics

Target Recruit Count: 1800

Registration Number: NCT06736574

Locations: 🇺🇸
Capital Area Research, LLC, Camp Hill, Pennsylvania, United States

A Study to Evaluate the Effect of Aficamten in Pediatric Patients (Age 12 to <18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Phase 2

Recruiting

Conditions: Pediatric
Symptomatic Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Aficamten
Drug: Placebo

First Posted Date: 2024-05-14

Last Posted Date: 2024-10-22

Lead Sponsor: Cytokinetics

Target Recruit Count: 40

Registration Number: NCT06412666

Locations: 🇺🇸
Morristown Medical Center, Morristown, New Jersey, United States
🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM

Phase 3

Recruiting

Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Placebo
Drug: Aficamten

First Posted Date: 2023-10-13

Last Posted Date: 2024-12-04

Lead Sponsor: Cytokinetics

Target Recruit Count: 420

Registration Number: NCT06081894

Locations: 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸
Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States
🇧🇷
Fundacao Felice Rocho / Hospital Felicio Rocho, Minas Gerais, Brazil

and more 81 locations

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Aficamten
Drug: Aficamten-matching Placebo
Drug: Moxifloxacin

First Posted Date: 2023-06-29

Last Posted Date: 2023-12-19

Lead Sponsor: Cytokinetics

Target Recruit Count: 44

Registration Number: NCT05924815

Locations: 🇺🇸
Celerion, Inc 2420, Tempe, Arizona, United States

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Placebo for CK-4021586
Drug: CK-4021586

First Posted Date: 2023-05-26

Last Posted Date: 2024-08-07

Lead Sponsor: Cytokinetics

Target Recruit Count: 132

Registration Number: NCT05877053

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Phase 3

Recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions: Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
Drug: Placebo to match aficamten
Drug: Placebo to match metoprolol succinate
Drug: Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)

First Posted Date: 2023-03-14

Last Posted Date: 2024-07-16

Lead Sponsor: Cytokinetics

Target Recruit Count: 170

Registration Number: NCT05767346

Locations: 🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇩🇪
Universitaetsklinikum Jena, Jena, Germany
🇩🇪
Charite-Universitatsmedizin Berlin - Campus Virchow Klinikum, Berlin, Germany

and more 68 locations

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

Phase 1

Terminated

Conditions: Healthy Participants

Interventions: Drug: Placebo for CK-3828136
Drug: CK-3828136

First Posted Date: 2022-12-22

Last Posted Date: 2024-10-17

Lead Sponsor: Cytokinetics

Target Recruit Count: 57

Registration Number: NCT05662215

Locations: 🇺🇸
Labcorp Clinical Research Unit Inc., Dallas, Texas, United States

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Reldesemtiv

First Posted Date: 2022-07-05

Last Posted Date: 2024-08-13

Lead Sponsor: Cytokinetics

Target Recruit Count: 71

Registration Number: NCT05442775

Locations: 🇺🇸
University of California Irvine - ALS & Neuromuscular Center, Orange, California, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Michigan Medicine, Ann Arbor, Michigan, United States

and more 38 locations

Efficacy and Safety Trial of Aficamten vs Placebo in Adults With Symptomatic oHCM (SEQUOIA-HCM)

Phase 3

Completed

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions: Drug: CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)
Drug: Placebo to match CK-3773274

First Posted Date: 2022-01-11

Last Posted Date: 2024-12-02

Lead Sponsor: Cytokinetics

Target Recruit Count: 282

Registration Number: NCT05186818

Locations: 🇺🇸
Cedars-Sinai Medical Center - Smidt Heart Institute Clinic, Los Angeles, California, United States
🇺🇸
MedStar Medical Group Cardiology at Union Memorial, Baltimore, Maryland, United States
🇺🇸
Medstar Franklin Square Medical Center, Baltimore, Maryland, United States

and more 110 locations

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Reldesemtiv
Drug: Placebo

First Posted Date: 2021-06-30

Last Posted Date: 2024-12-05

Lead Sponsor: Cytokinetics

Target Recruit Count: 489

Registration Number: NCT04944784

Locations: 🇺🇸
Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 81 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy